{"name":"Prairie Eye Center","slug":"prairie-eye-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Simbrinza 0.2%-1% Ophthalmic Suspension","genericName":"Simbrinza 0.2%-1% Ophthalmic Suspension","slug":"simbrinza-0-2-1-ophthalmic-suspension","indication":"Open-angle glaucoma","status":"marketed"},{"name":"Cosopt PF 2%-0.5% Ophthalmic Solution","genericName":"Cosopt PF 2%-0.5% Ophthalmic Solution","slug":"cosopt-pf-2-0-5-ophthalmic-solution","indication":"Open-angle glaucoma","status":"marketed"}]}],"pipeline":[{"name":"Simbrinza 0.2%-1% Ophthalmic Suspension","genericName":"Simbrinza 0.2%-1% Ophthalmic Suspension","slug":"simbrinza-0-2-1-ophthalmic-suspension","phase":"marketed","mechanism":"Simbrinza combines a beta-adrenergic antagonist and a carbonic anhydrase inhibitor to reduce intraocular pressure by decreasing aqueous humor production.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Cosopt PF 2%-0.5% Ophthalmic Solution","genericName":"Cosopt PF 2%-0.5% Ophthalmic Solution","slug":"cosopt-pf-2-0-5-ophthalmic-solution","phase":"marketed","mechanism":"Cosopt PF combines a topical carbonic anhydrase inhibitor (dorzolamide) and a beta-blocker (timolol) to reduce intraocular pressure through decreased aqueous humor production.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9rdTR4WGVrblFnQWgzczdpblJRQTljWl9fdlRrR1p6cUYyeUtJU1N2c04xeWVRZGpPQ2hDLWFPdE1rOG5USEhobjhFd190cGhPRGNDMDdlWlZKdjRzb3dwR1R1TjJEWTlBZV93?oc=5","date":"2025-10-14","type":"pipeline","source":"instyle.com","summary":"Trust Us, You Deserve to Splurge—14 of Our Editors’ Favorite Luxury Skin Care Brands Worth Investing In - instyle.com","headline":"Trust Us, You Deserve to Splurge—14 of Our Editors’ Favorite Luxury Skin Care Brands Worth Investing In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPLThiSHlTR2R5UDN2YXNma084amYwQXZMODdnaENyMVM4djNPZXVFd0l2aVNqczdsWEhlUjhETjEyVkJLWEVUWWJtUzNDdnIwV3ZkcEY1bFZQalQ3QXBHOW96T0ZjVzZmN3h5N3RwUm9XVW5OY19NVnZFZEd0OTdEU25VZG5qaVZmdUg2cTE3VQ?oc=5","date":"2024-06-24","type":"pipeline","source":"Star Tribune","summary":"ANI Pharmaceuticals bolsters rare disease business with $381M eye care company acquisition - Star Tribune","headline":"ANI Pharmaceuticals bolsters rare disease business with $381M eye care company acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPTVZyV29RdUlPYTNHYVotclRlOEs4VWVDdU5wb2hBcFNMOXpVeFNHTms2Ymd6LUJ5bTJvZU9SYzFpVlJRdXoyQzg1SWRrUkU0YjJvSWtlNFU1UUxDc2J2Vmk5elVscnR6ZS1tRUx3RHItcDc3bFBOeXZUbnFoTGRRV0s5anJWSGxs?oc=5","date":"2024-05-21","type":"pipeline","source":"Private Equity Stakeholder Project PESP","summary":"Private Equity Healthcare Acquisitions – April 2024 - Private Equity Stakeholder Project PESP","headline":"Private Equity Healthcare Acquisitions – April 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9rRkNMUWUxVXpYRzBHT0ZSNmtzUHd0RHFnVTBHV2JnY00yaXNqWWJCNmVxNlBDX1huY1A2VFBUX1RvS29xRWNWenI4OFItZzcwU0VNdThIUWpOVDA0VmpKLUM0SGtZbzRyYXZrN2wtdWpfUDRNNU9ldjZPRkwtZw?oc=5","date":"2024-04-26","type":"pipeline","source":"Racine County Eye","summary":"Eli Lilly’s acquisition of Nexus facility marks a new era for Pleasant Prairie’s pharmaceutical landscape - Racine County Eye","headline":"Eli Lilly’s acquisition of Nexus facility marks a new era for Pleasant Prairie’s pharmaceutical landscape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNcVlyRjQxVGpxdkpZa1NNRmtONllVV0ZXemJ4QWtGT193OFc1bENHSGhKNzhzYng1NnBjVFdQXzgtZlFwQW1zUnJyTi1QT2hFSWFCMG5RMUh2YzU2ZWhyZUlUQzh6eElTelJLVlF6T0xCTzdvVGpQQ1piUWVTSmZUcndiTzRQVTdYNlJpTQ?oc=5","date":"2021-11-29","type":"pipeline","source":"Private Equity Stakeholder Project PESP","summary":"Private Equity Health Care Acquisitions – October 2021 - Private Equity Stakeholder Project PESP","headline":"Private Equity Health Care Acquisitions – October 2021","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}